SOLIFENACIN SUCCINATE UMEDICA

Posology Adults, including the elderly The recommended dose is 5 mg Solifenacin succinate once daily. If needed, the dose may be increased to 10 mg Solifenacin succinate once daily. Paediatric population The safety and efficacy of solifenacin succinate in children have not yet been established.

Therefore, solifenacin succinate should not be used in children. Patients with renal impairment No dose adjustment is necessary for patients with mild to moderate renal impairment (creatinine clearance > 30 ml/min). 2). Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment.

2). g. 5). Method of administration Solifenacin succinate Umedica 5 mg film-coated tablets should be taken orally and should be swallowed whole with liquids. It can be taken with or without food.

Summary of the safety profile Due to the pharmacological effect of solifenacin, Solifenacin succinate may cause anticholinergic undesirable effects of (in general) mild or moderate severity. The frequency of anticholinergic undesirable effects is dose related.

The most commonly reported adverse reaction with Solifenacin succinate was dry mouth. It occurred in 11% of patients treated with 5 mg once daily, in 22% of patients treated with 10 mg once daily and in 4% of placebo-treated patients.

The severity of dry mouth was generally mild and did only occasionally lead to discontinuation of treatment. In general, medicinal product compliance was very high (approximately 99%) and approximately 90% of the patients treated with Solifenacin succinate completed the full study period of 12 weeks treatment.

Tabulated list of adverse reactions MedDRA system organ class Very common ≥1/10 Common ≥1/100, <1/10 Uncommon ≥1/1000, <1/100 Rare ≥ 1/10000, <1/1000 Very rare <1/10,000 Not known (cannot be estimated from the available data) Infections and infestations Urinary tract infection Cystitis Immune system disorders Anaphylactic reaction* Metabolism and nutrition disorders Decreased appetite* Hyperkalaemia* Psychiatric disorders Hallucinations* Confusional state* Delirium* Nervous system disorders Somnolence Dysgeusia Dizziness*, Headache* Eye disorders Blurred vision Dry eyes Glaucoma* Cardiac disorders Torsade de Pointes* Electrocardiogram QT prolonged* Atrial fibrillation* Palpitations* *observed post-marketing Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment with Solifenacin succinate. If urinary tract infection is present, an appropriate antibacterial therapy should be started. Solifenacin succinate should be used with caution in patients with: - clinically significant bladder outflow obstruction at risk of urinary retention.

- gastrointestinal obstructive disorders. - risk of decreased gastrointestinal motility. 2), and doses should not exceed 5 mg for these patients. 2), and doses should not exceed 5 mg for these patients. g. 5). - hiatus hernia/gastro-oesophageal reflux and/or who are concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate oesophagitis.

- autonomic neuropathy. QT prolongation and Torsade de Pointes have been observed in patients with risk factors, such as pre-existing long QT syndrome and hypokalaemia. Safety and efficacy have not yet been established in patients with a neurogenic cause for detrusor overactivity.

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. Angioedema with airway obstruction has been reported in some patients on solifenacin succinate.

If angioedema occurs, Solifenacin succinate should be discontinued and appropriate therapy and/or measures should be taken. Anaphylactic reaction has been reported in some patients treated with solifenacin succinate. In patients who develop anaphylactic reactions, Solifenacin succinate should be discontinued and appropriate therapy and/or measures should be taken.

The maximum effect of solifenacin succinate can be determined after 4 weeks at the earliest.

Solifenacin is contraindicated in patients with urinary retention, severe gastro- intestinal condition (including toxic megacolon), myasthenia gravis or narrow- angle glaucoma and in patients at risk for these conditions. 1. 2). 2). g.

5).